1. Levin VA, Leibel SA, Gutin PH. Neoplasms of the central nervous system. In: DeVita VT Jr, Hellman S, Rosenberg SA, editors. Cancer: Principles and Practice of Oncology. Philadelphia: Lippincott; 1989. pp. 1557–1611.
2. Cohen KJ, Broniscer A, Glod J. Pediatric glial tumors. Curr Treat Options Oncol. 200;2:529–536. [PubMed] 3. Jennings MT, Sposto R, Boyett JM, et al. Preradiation chemotherapy in primary high-risk brainstem tumors: phase II study CCG-9941 of the Children’s Cancer Group. J Clin Oncol. 2002;20:3431–3437. [PubMed] 4. Kaplan AM, Albright AL, Zimmerman RA, et al. Brainstem gliomas in children: a Children’s Cancer Group review of 119 cases. Pediatr Neurosurg. 1996;24:185–192. [PubMed] 5. Smith MA, Freidlin B, Ries LA, Simon R. Trends in reported incidence of primary malignant brain tumors in children in the United States. J Natl Cancer Inst. 1998;90:1269–1277. [PubMed] 6. Gilbertson RJ, Hill DA, Hernan R, et al. ERBB1 is amplified and overexpressed in high-grade diffusely infiltrative pediatric brain stem glioma. Clin Cancer Res. 2003;9:3620–3624. [PubMed] 7. Laske DW, Youle RJ, Oldfield EH. Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors. Nat Med. 1997;3:1362–1368. [PubMed] 8. Puri RK, Hoon DS, Leland P, et al. Preclinical development of a recombinant toxin containing circularly permuted interleukin 4 and truncated Pseudomonas exotoxin for therapy of malignant astrocytoma. Cancer Res. 1996;56:5631–5637. [PubMed] 9. Puri R, Leland P, Kreitman R, Pastan I. Human neurological cancer cells express interleukin-4 (IL-4) receptors which are targets for the toxic effects of IL4–Pseudomonas exotoxin chimeric protein. Int J Cancer. 1994;58:574–581. [PubMed] 10. Debinski W, Obiri NI, Powers SK, Pastan I, Puri RK. Human glioma cells overexpress receptors for interleukin 13 and are extremely sensitive to a novel chimeric protein composed of interleukin 13 and pseudomonas exotoxin. Clin Cancer Res. 1995;1:1253–1258. [PubMed] 11. Debinski W, Miner R, Leland P, Obiri NI, Puri RK. Receptor for interleukin (IL) 13 does not interact with IL4 but receptor for IL4 interacts with IL13 on human glioma cells. J Biol Chem. 1996;271:22428–22433. [PubMed] 12. Batra JK, Fitzgerald DJ, Chaudhary VK, Pastan I. Single-chain immunotoxins directed at the human transferrin receptor containing Pseudomonas exotoxin A or diphtheria toxin: anti-TFR(Fv)-PE40 and DT388–anti-TFR(Fv) Mol Cell Biol. 1991;11:2200–2205. [PMC free article] [PubMed] 13. Murata T, Obiri NI, Debinski W, Puri RK. Structure of IL-13 receptor: analysis of subunit composition in cancer and immune cells. Biochem Biophys Res Commun. 1997;238:90–94. [PubMed] 14. Joshi BH, Hogaboam C, Dover P, Husain SR, Puri RK. Role of interleukin-13 in cancer, pulmonary fibrosis, and other T(H)2-type diseases. Vitam Horm. 2006;74:479–504. [PubMed] 15. Murata T, Obiri NI, Puri RK. Structure of and signal transduction through interleukin-4 and interleukin-13 receptors (review) Int J Mol Med. 1998;1:551–557. [PubMed] 16. Obiri NI, Leland P, Murata T, Debinski W, Puri RK. The IL-13 receptor structure differs on various cell types and may share more than one component with IL-4 receptor. J Immunol. 1997;158:756–764. [PubMed] 17. Obiri NI, Murata T, Debinski W, Puri RK. Modulation of interleukin (IL)-13 binding and signaling by the gamma c chain of the IL-2 receptor. J Biol Chem. 1997;272:20251–20258. [PubMed] 18. Obiri NI, Debinski W, Leonard WJ, Puri RK. Receptor for interleukin 13. Interaction with interleukin 4 by a mechanism that does not involve the common gamma chain shared by receptors for interleukins 2, 4, 7, 9, and 15. J Biol Chem. 1995;270:8797–8804. [PubMed] 19. Kuznetsov VA, Puri RK. Kinetic analysis of high affinity forms of interleukin (IL)-13 receptors: suppression of IL-13 binding by IL-2 receptor gamma chain. Biophys J. 1999;77:154–172. [PubMed] 20. Murata T, Husain SR, Mohri H, Puri RK. Two different IL-13 receptor chains are expressed in normal human skin fibroblasts, and IL-4 and IL-13 mediate signal transduction through a common pathway. Int Immunol. 1998;10:1103–1110. [PubMed] 21. Murata T, Noguchi PD, Puri RK. IL-13 induces phosphorylation and activation of JAK2 Janus kinase in human colon carcinoma cell lines: similarities between IL-4 and IL-13 signaling. J Immunol. 1996;156:2972–2978. [PubMed] 22. Wood N, Whitters MJ, Jacobson BA, et al. E nhanced interleukin (IL)-13 responses in mice lacking IL-13 receptor alpha 2. J Exp Med. 2003;197:703–709. [PMC free article] [PubMed] 23. Rahaman SO, Sharma P, Harbor PC, Aman MJ, Vogelbaum MA, Haque SJ. IL-13R(alpha)2, a decoy receptor for IL-13 acts as an inhibitor of IL-4–dependent signal transduction in glioblastoma cells. Cancer Res. 2002;62:1103–1109. [PubMed] 24. Rahaman SO, Vogelbaum MA, Haque SJ. Aberrant Stat3 signaling by interleukin-4 in malignant glioma cells: involvement of IL-13Ralpha2. Cancer Res. 2005;65:2956–2963. [PubMed] 25. Fichtner-Feigl S, Strober W, Kawakami K, Puri RK, Kitani A. IL-13 signaling through the IL-13alpha(2) receptor is involved in induction of TGF-beta(1) production and fibrosis. Nat Med. 2006;12:99–106. [PubMed] 26. Debinski W, Obiri NI, Pastan I, Puri RK. A novel chimeric protein composed of interleukin 13 and Pseudomonas exotoxin is highly cytotoxic to human carcinoma cells expressing receptors for interleukin 13 and interleukin 4. J Biol Chem. 1995;270:16775–16780. [PubMed] 27. Maini A, Hillman G, Haas GP, et al. Interleukin-13 receptors on human prostate carcinoma cell lines represent a novel target for a chimeric protein composed of IL-13 and a mutated form of Pseudomonas exotoxin. J Urol. 1997;158:948–953. [PubMed] 28. Husain SR, Puri RK. Interleukin-13 fusion cytotoxin as a potent targeted agent for AIDS-Kaposi’s sarcoma xenograft. Blood. 2000;95:3506–3513. [PubMed] 29. Joshi BH, Husain SR, Puri RK. Preclinical studies with IL-13PE38QQR for therapy of malignant glioma. Drug News Perspect. 2000;13:599–605. [PubMed] 30. Kawakami K, Kawakami M, Joshi BH, Puri RK. Interleukin-13 receptor-targeted cancer therapy in an immunodeficient animal model of human head and neck cancer. Cancer Res. 2001;61:6194–6200. [PubMed] 31. Kioi M, Husain SR, Croteau D, Kunwar S, Puri RK. Convection-enhanced delivery of interleukin-13 receptor-directed cytotoxin for malignant glioma therapy. Technol Cancer Res Treat. 2006;5:239–250. [PubMed] 32. Husain SR, Joshi BH, Puri RK. Interleukin-13 receptor as a unique target for anti-glioblastoma therapy. Int J Cancer. 2001;92:168–175. [PubMed] 33. Husain SR, Gill P, Kreitman RJ, Pastan I, Puri RK. Interleukin-4 receptor expression on AIDS-associated Kaposi’s sarcoma cells and their targeting by a chimeric protein comprised of circularly permuted interleukin-4 and Pseudomonas exotoxin. Mol Med. 1997;3:327–338. [PMC free article] [PubMed] 34. Kawakami K, Joshi BH, Puri RK. Sensitization of cancer cells to interleukin 13-pseudomonas exotoxin-induced cell death by gene transfer of interleukin 13 receptor alpha chain. Hum Gene Ther. 2000;11:1829–1835. [PubMed] 35. Kawakami K, Husain SR, Bright RK, Puri RK. Gene transfer of interleukin 13 receptor alpha2 chain dramatically enhances the antitumor effect of IL-13 receptor-targeted cytotoxin in human prostate cancer xenografts. Cancer Gene Ther. 2001;8:861–868. [PubMed]
36. Croteau D, Kunwar S, Ram Z, et al. A cytokine tumor targeting agent, IL-13PE38QQR (cintredekin besudotox), administered by intraparenchymal convection-enhanced delivery (CED) for the treatment of recurrent malignant glioma (MG) brain tumors. Presentation at Cytokines and inflammation; San Diego, CA. 2006.
37. Kunwar S, Pai LH, Pastan I. Cytotoxicity and antitumor effects of growth factor-toxin fusion proteins on human glioblastoma multiforme cells. J Neurosurg. 1993;79:569–576. [PubMed]
38. Kunwar S, Prados M, Chang SM, et al. Convection-enhanced delivery of IL-13PE38QQR: results of a multicenter phase I study in recurrent malignant glioma. Presentation at the annual meeting of the American Association of Neurological Surgeons; New Orleans, LA. 2005.
39. Kunwar S, Ram Z, Sampson JH, et al. Peritumoral convection-enhanced delivery (CED) of IL-13PE38QQR (IL13PE): results of multicenter phase 1 studies in recurrent high grade glioma (HGG) Neuro-Oncology. 2005;7:114.
40. Lang F, Kunwar S, Strauss L, et al. A clinical study of convection-enhanced delivery of IL-13PE38QQR cytotoxin pre- and post-resection of recurrent GBM. Presentation at the meeting of the American Society of Neuro-Oncologists; Chicago. April 2002.
41. Prados M, Kunwar S, Lang F, et al. Final results of phase I/II studies of IL-13PE38QQR administered intratumorally (IT) and/or peritumorally (PT) via convection-enhanced delivery (CED) in patients undergoing tumor resection for recurrent malignant glioma. J Clin Oncol. 2005;23:115S.
42. Prados M, Lang F, Strauss L, et al. Intratumoral and intracerebral microinfusion of Il13–PE38QQR cytotoxin: phase I/II study of pre- and post-resection infusions in recurrent resectable malignant glioma. Presentation at the 8th annual meeting of the American Society of Clinical Oncology; Orlando, FL. May 18–21, 2002; abstract 2087.
43. Prados M, Lang F, Strauss L, et al. Pre and post-resection interstitial infusions of IL13-PE38QQR cytotoxin: phase I study in recurrent respectable malignant glioma. Presentation at the First Quadrennial Meeting of the World Federation of Neuro-Oncology; Washington, DC. November 15–November 17, 2001.
44. Sampson JH, Friedman AH, Reardon DA, et al. Convection-enhanced delivery of IL-13PE38QQR in malignant glioma: effect of catheter placement on drug distribution. J Neurosurg. 2004;100:A772.
45. Weingart J, Grossman SA, Bohan E, Fisher JD, Strauss L, Puri RK. Phase I/II study of interstitial infusion of IL13–PE38QQR cytotoxin in recurrent malignant glioma. Presentation at the First Quadrennial Meeting of the World Federation of Neuro-Oncology; Washington, DC. November 15–17, 2001.
46. Weingart J, Strauss L, Grossman SA, et al. Phase I/II study: intra-tumoral infusion of IL13-PE38QQR cytotoxin for recurrent supratentorial malignant glioma. Neuro-Oncology. 2002;4:379.
47. Weingart J, Tatter SSR, Mikkelsen T, et al. Intratumoral convection-enhanced delivery of IL-13PE38QQR cytototxin for recurrent malignant glioma without planned resection: a phase I/II study. Presentation at the 8th annual meeting of the Society for Neuro-Oncology; Keystone, CO. 2003.
48. Kunwar S, Prados MD, Chang SM, et al. Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study Group. J Clin Oncol. 2007;25:837–844. [PubMed] 49. Joshi BH, Plautz GE, Puri RK. Interleukin-13 receptor alpha chain: a novel tumor-associated transmembrane protein in primary explants of human malignant gliomas. Cancer Res. 2000;60:1168–1172. [PubMed] 50. Kawakami M, Kawakami K, Takahashi S, Abe M, Puri RK. Analysis of interleukin-13 receptor alpha2 expression in human pediatric brain tumors. Cancer. 2004;101:1036–1042. [PubMed] 51. Gilbertson RJ, Perry RH, Kelly PJ, Pearson AD, Lunec J. Prognostic significance of HER2 and HER4 coexpression in childhood medulloblastoma. Cancer Res. 1997;57:3272–3280. [PubMed]
52. Debinski W, Hulet SW, Connor JR, Gillespie GY, Puri R. Overexpression of a receptor for Interleukin 13 in human glioblastoma multiforme detected in situ. Presentation at the 2nd annual meeting of the Society for Neuro-Oncology; Charlottesville, VA. 1997.
53. Murata T, Taguchi J, Puri RK, Mohri H. Sharing of receptor subunits and signal transduction pathway between the IL-4 and IL-13 receptor system. Int J Hematol. 1999;69:13–20. [PubMed] 54. Kawakami M, Leland P, Kawakami K, Puri RK. Mutation and functional analysis of IL-13 receptors in human malignant glioma cells. Oncol Res. 2000;12:459–467. [PubMed]
55. Joshi B, Husain SR, Leland P, Puri R. Interleukin-13 receptors and development of IL-13 Pseudomonas exotoxin for human cancer therapy. In: Kawakami K, Aggarwal BB, Puri R, editors. Cytotoxins and Immunotoxins for Cancer Therapy: Clinical Applications. Boca Raton, FL: CRC Press; 2005. pp. 45–69.
56. Husain SR, Puri RK. Interleukin-13 receptor-directed cytotoxin for malignant glioma therapy: from bench to bedside. J Neurooncol. 2003;65:37–48. [PubMed] 57. Husain SR, Obiri NI, Gill P, et al. Receptor for interleukin 13 on AIDS-associated Kaposi’s sarcoma cells serves as a new target for a potent Pseudomonas exotoxin-based chimeric toxin protein. Clin Cancer Res. 1997;3:151–156. [PubMed] 59. Kawakami K, Kawakami M, Puri RK. IL-13 receptor-targeted cytotoxin cancer therapy leads to complete eradication of tumors with the aid of phagocytic cells in nude mice model of human cancer. J Immunol. 2002;169:7119–7126. [PubMed]
60. Kunwar S, Prados M, Lang F, et al. Intratumoral and peritumoral convection-enhanced delivery of IL-13PE38QQR, a recombinant tumor-targeted cytotoxin in a recurrent malignant glioma phase I trial. J Neurosurg. 2003;98:697.
61. Murad GJ, Walbridge S, Morrison PF, et al. Real-time, image-guided, convection-enhanced delivery of interleukin 13 bound to Pseudomonas exotoxin. Clin Cancer Res. 2006;12:3145–3151. [PubMed]